Comparison of the vessel healing process after everolimus-eluting stent and bare metal stent implantations in patients with ST-elevation myocardial infarction

被引:0
作者
Hideki Yano
Shigeo Horinaka
Manami Watahik
Tomoko Watanabe
Toshihiko Ishimitsu
机构
[1] Dokkyo Medical University Hospital,Department of Cardiology and Nephrology
[2] Nasu Red Cross Hospital,Department of Cardiology
来源
Heart and Vessels | 2019年 / 34卷
关键词
Everolimus-eluting stent; Optical coherence tomography; ST-elevation myocardial infarction; Neointimal thickness; Apposition; Stent strut coverage;
D O I
暂无
中图分类号
学科分类号
摘要
Cobalt–chromium everolimus-eluting stent (CoCr EES) is associated with a lower rate of stent thrombosis even in patients with ST-elevation myocardial infarction (STEMI). However, the time-serial changes of endothelial coverage of the stent struts in the extremely early period have never been reported, especially in patients with STEMI. The aim of this study was to compare the vessel healing process between CoCr EES and cobalt–chromium bare metal stent (CoCr BMS) implantations using optical coherence tomography (OCT) in patients with STEMI. Sixty-three patients who had primary emergent percutaneous coronary intervention (PCI) with CoCr EES (42 patients) or CoCr BMS (21 patients) were enrolled in this study for 3 years. OCT was performed just after, 2 and 12 weeks after EES or BMS implantations. Time-serial changes in the neointimal coverage (NIC), the neointimal thickness, and malapposition of stent struts were evaluated. NIC of stent struts did not differ between CoCr EES (23.2%, 99.4%) and CoCr BMS (24.0%, 97.8%) at 2 weeks and 12 weeks after PCI, respectively. Thicknesses of the neointima on the stent strut was significantly thinner in CoCr EES (34.0 ± 13.8, 107.0 ± 32.4 µm) than in CoCr BMS (40.0 ± 14.6, 115.7 ± 33.8 µm) at 2 weeks and 12 weeks after PCI (p = 0.011, p = 0.008), respectively. The malapposition did not differ just after PCI, and was completely resolved at 12 weeks after PCI in both groups. Thrombus was significantly less in CoCr EES than in CoCr BMS at 2 weeks (19.0% vs 42.9%, p < 0.01), and decreased over time in both groups, but at 12 weeks, disappeared only in CoCr EES (CoCr EES: 0% vs. CoCr BMS: 4.8%, p = 0.56). This study demonstrated that NIC and apposition of the stent struts almost completed at 12 weeks after EES and BMS implantations, while the neointimal thickness on the stent struts were thinner in EES than in BMS. Moreover, thrombus was significantly less in EES than in BMS implantations 2 weeks after PCI, which may explain the lower rate of acute and subacute stent thrombosis of EES compared with BMS.
引用
收藏
页码:572 / 582
页数:10
相关论文
共 533 条
  • [1] Horst B(2009)Comparison of drug-eluting and bare-metal stents for stable coronary artery disease JACC Cardiovasc Interv 2 321-328
  • [2] Rihal CS(2007)Outcomes associated with drug-eluting and bare-metal stents: a collaborative network metaanalysis Lancet 370 937-948
  • [3] Holmes DR(2004)A hierarchical Bayesian meta-analysis of randomized clinical trials of drug-eluting stents Lancet 364 583-591
  • [4] Bresnahan JF(2004)Stent thrombosis after successful sirolimus-eluting stent implantation Circulation 109 1930-1932
  • [5] Prasad A(2006)Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J Am Coll Cardiol 48 193-202
  • [6] Gau G(2004)Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109 701-705
  • [7] Lennon R(2007)Pathological correlates of late drugeluting stent thrombosis: strut coverage as a marker of endothelialization Circulation 115 2435-2441
  • [8] Lerman A(2008)Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V) Vasc Health Risk Manag 4 31-38
  • [9] Stettler C(2006)A randomized comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial EuroIntervention 2 286-294
  • [10] Wandel S(2011)Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) trials JACC Cardiovasc Interv 4 1104-1115